8月10日 - ** Silence Therapeutics（SLNCF.PK, SLN.O）在美上市股票上涨35%，至16.17美元，创下20个月以来的新高
** 该公司表示，其实验性药物divesiran在治疗真性红细胞增多症（一种罕见血液癌症）的中期临床试验中达到了主要目标
** 接受divesiran治疗的患者反应率达88%，而安慰剂组仅为19%
** Cantor分析师阿格拉瓦尔 (Prakhar Agrawal)称该数据“非常出色”，并指出divesiran的疗效“显著超过”武田制药（4502.T）和Protagonist公司（PTGX.O）的竞争药物rusfertide
** 该公司表示，该药物显著减少了血液去除和放血治疗的需求，并有助于控制患者的血液黏稠度
** 该公司计划于2027年上半年启动一项后期临床试验
** 算上本次交易，该股年初至今涨幅已超过一倍
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.